IFNAR1 and diabetes mellitus: In the rapid-onset RIP-LCMV model (RIP-GP), although viral titer was increased, treatment of anti-Ifn-α or anti-Ifnar antibodies completely prevented the incidence of diabetes after LCMV infection, but treatment with anti-Ifn-β antibody did not [125].